Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation. (16th November 2022)

• Record Type: Journal Article
• Authors: Bankova, Andriyana K.; Pasin, Chloé; Huang, Alice; Cicin‐Sain, Caroline; Epp, Selina; Audige, Annette; Mueller, Nicolas J.; Nilsson, Jakob; Vilinovszki, Oliver; Nair, Gayathri; Wolfensberger, Nathan; Hockl, Philipp; Schanz, Urs; Trkola, Alexandra; Kouyos, Roger; Hasse, Barbara; Zinkernagel, Annelies S.; Manz, Markus G.; Abela, Irene A.; Müller, Antonia M. S.
• Is Part Of: British journal of haematology. Volume 201:Number 1(2023)
• Page Start: 58
• Page End: 63
• Publication Date: 2022-11-16
• Subjects: allogeneic haematopoietic cell transplantation -- severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) -- vaccine response; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.18562
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Allogeneic haematopoietic cell transplantation (allo‐HCT) recipients show impaired antibody (Ab) response to a standard two‐dose vaccination against severe acute respiratory syndrome coronavirus‐2 and currently a third dose is recommended as part of the primary vaccination regimen. By assessing Ab titres 1 month after a third mRNA vaccine dose in 74 allo‐HCT recipients we show sufficient neutralisation activity in 77% of the patients. Discontinuation of immunosuppression before the third vaccine led to serological responses in 50% of low responders to two vaccinations. Identifying factors that might contribute to better vaccine responses in allo‐HCT recipients is critical to optimise current vaccination strategies.